VentfortvsLivagen

Molecular Formula

Complex peptide mixture (multiple sequences, MW range up to ₅ kDa; active component KED: C₁₃H₂₂N₄O₇)

Molecular Weight

Complex mixture up to 5,000 Da; KED active tripeptide: ~362.3 g/mol

Half-Life

Short plasma half-life typical of ultrashort peptides (minutes to hours); biological effects persist for weeks to months through epigenetic modifications to vascular gene expression; metabolized to constituent amino acids

Bioavailability

Oral formulation absorbed via intestinal peptide transporters; ultrashort peptides in the complex have efficient cellular uptake; injectable form provides direct systemic delivery; tissue-derived peptides maintain bioactivity through enteric-coated capsule formulation

CAS Number

Not applicable (tissue-derived complex)

Molecular Formula

C₁₈H₃₁N₅O₉

Molecular Weight

461.5 g/mol

Half-Life

Short plasma half-life typical of tetrapeptides; biological effects persist for weeks through epigenetic chromatin remodeling modifications; metabolized to constituent amino acids (lysine, glutamic acid, aspartic acid, alanine)

Bioavailability

Resistant to intestinal proteolysis when administered orally (weakly hydrolyzed by intestinal peptidases); efficient absorption from intramuscular injection sites; penetrates cytoplasmic and nuclear membranes to reach cell nuclei and nucleoli

CAS Number

Not assigned (research compound)

Common

• Injection site reaction
• Mild fatigue
• Mild headache
• Mild blood pressure fluctuation

Uncommon

• Mild dizziness

Serious

• No documented serious adverse effects

Common

• Injection site reaction
• Mild fatigue
• Mild headache
• Digestive enzyme changes

Uncommon

• Transient flu-like symptoms

Serious

• No documented serious adverse effects

Evidence Level

Limited human trials

FDA Status

Research compound

Safety Overview

Ventfort (collagen peptide complex) demonstrates excellent safety profile from cosmetic and nutritional supplement use spanning decades. Hydrolyzed collagen peptides pass through the GI tract largely unchanged—minimal systemic absorption occurs, making serious adverse effects unlikely. Mild gastrointestinal side effects (bloating, dyspepsia) occur in <5% of users and are generally self-limiting. Allergic reactions are rare given the high molecular weight peptide fragments; histamine content is negligible in properly processed formulations.

Contraindications

• xKnown hypersensitivity to bovine-derived peptide products or any constituent amino acids
• xActive bleeding disorders or concurrent anticoagulant therapy without medical supervision
• xSevere cardiovascular disease requiring immediate medical intervention
• xPregnancy and breastfeeding — insufficient reproductive safety data

Evidence Level

Limited human trials

FDA Status

Research compound

Safety Overview

Livagen (a liver-derived peptide extract) carries a safety profile established through decades of use in Eastern European hepatology and gastroenterology clinics. As an organ-derived extract rather than a synthetic single peptide, it contains multiple bioactive components promoting hepatocyte regeneration and cytoprotection. Adverse events are minimal in reported clinical experience—mild gastrointestinal upset occurring in <5% of patients. The compound shows no hepatotoxicity, nephrotoxicity, or immunosensitization in available safety surveillance data from thousands of patients.

Contraindications

• xKnown hypersensitivity to peptide bioregulators or constituent amino acids (lysine, glutamic acid, aspartic acid, alanine)
• xPregnancy and breastfeeding — insufficient reproductive safety data
• xActive autoimmune conditions in flare without physician supervision
• xConcurrent use of opioid medications — Livagen's enkephalinase inhibition may alter opioid metabolism